Optimum News

ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology

ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical Company Limited … Continue reading “ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology”

By Optimum

GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

• Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. • The two companies will leverage their combined scientific, commercial and market access expertise to … Continue reading “GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer”

By Optimum

Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company’s lead compound Nefecon, … Continue reading “Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon”

By Optimum

OCTIMET expands ongoing proof of concept study to evaluate the combination of highly selective MET Kinase Inhibitor OMO-1 with EGFR TKIs

OMO-1 has potential to treat cancer as a monotherapy and in combination with EGFR TKIs for patients becoming resistant to or progressing on treatment Beerse, Belgium, 25 September 2019 – … Continue reading “OCTIMET expands ongoing proof of concept study to evaluate the combination of highly selective MET Kinase Inhibitor OMO-1 with EGFR TKIs”

By Optimum

STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes

Data to be presented at inaugural STORM Therapeutics RNA Epigenetics in Human Disease Conference in Cambridge, UK 18 September 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the … Continue reading “STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes”

By Optimum

Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis … Continue reading “Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH